Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.

Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Annie Fällström and Amanda Sandström.

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025